Air Pollution Linked to Autoimmune Diseases PDF Print E-mail
Sunday, 31 January 2010 12:53
taken from http://www.flickr.com/photos/ikhlasulamal/4224395355/ via creative commonsMany people with environmental illnesses have an assortment of autoimmune diseases which scientists are linking to air pollution.

Though genetic factors have been found for autoimmune diseases, this knowledge has not helped to prevent them. In fact, according to researcher Stacy Ritz of the Northern Ontario School of Medicine, autoimmune diseases are rising at a dramatic rate.

"Population-level genetic changes cannot explain this trend; thus, environmental factors are strongly implicated," says Ritz in a recently published study. "Among the possible environmental contributors to autoimmune disease, air pollution exposure has received very little attention. Although there is only a small amount of published data directly examining a possible causal relationship between air pollution exposure and autoimmunity, data from related fields suggests that it could facilitate autoimmunity as well."

Antonella Zanobetti, a senior research scientist at the Harvard School of Public Health found that particulate matter in air pollution from industrial combustion and traffic significantly increased hospital admissions for cardiac problems, respiratory disease, and diabetes.

There are over 80 autoimmune diseases. Some of the more common ones include type 1 Diabetes, certain Thyroid and Adrenal disorders, Multiple Sclerosis, Scleroderma, Rheumatoid arthritis, Lupus, and Sjogren's Syndrome.

Autoimmune diseases are characterized by an immune response which leads to the destruction of the body´s own organs and tissues. They are frequently endocrine system related. Essentially the body treats its organs and tissues as though they were a foreign invader and the immune system kicks in to kill off the invader.

Many chemical pollutants are known endocrine disruptors. Though dose specific exposures may be considered safe, little research has been done on the cumulative and synergistic effects of the many multiple and unavoidable exposures humans are subjected to each day.

On a daily basis, humans are exposed to a chemical cocktail of pesticides, herbicides, automobile exhaust, and industrial pollution. Often overlooked sources of exposure may also be found in the home in the form of cleaning solutions, fragranced products, air freshener chemicals, and chemicals used in the manufacture of furniture, carpet, plastics, and other household goods.

Log in to download a copy of MCSA's newsletter containing the full article, below.

Source: MCSA News (2010), "Air Pollution Linked to Autoimmune Diseases", Vol. 5, Issue 2, February

 
More articles :

» Scleroderma Study Identifies Roadblocks To Employment

In the United States, the work disability rate for people with , also known as systemic sclerosis, is two to three times that of people with some other rheumatic conditions, according to research data from investigators at The (UTHealth) Medical...

» Cell Therapy Yields Promising Results For Scleroderma Treatment

Cytori Therapeutics, Inc. provided preliminary data from a study evaluating a potential treatment for Scleroderma based on the company's cell therapy. The investigator-funded, open-label, pilot study is being conducted on patients with Cutaneous...

» Scleroderma Drug In Development

According to , has partnered with , the health care investment arm of Morgan Keegan and Co. Inc., to jump-start a capital campaign to raise $12 million to $15 million. ArGentis shelved the campaign last year when the economy soured.The money will...

» Vascular Changes in Bleomycin-Induced Scleroderma

Toshiyuki Yamamoto and Ichiro KatayamaDepartment of Dermatology, Fukushima Medical University, Hikarigaoka 1, Fukushima 960-1295, JapanDepartment of Dermatology, Osaka University, Yamadaoka 2-2, Suita, Osaka 565-0871, JapanReceived 6 June 2011;...

» What You Should Know About The AntiNuclear Antibody Or ANA Test

How is it used?The ANA test is ordered to help screen for autoimmune disorders and is most often used as one of the tests to diagnose (SLE). Depending on the patient's symptoms and the suspected diagnosis, ANA may be ordered along with one or more...

» Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma

Amira Pharmaceuticals, Inc. announced today that their collaborators, Andrew Tager, M.D. and Flavia V. Castelino, M.D. of Massachusetts General Hospital, Harvard Medical School, will present a preclinical proof-of-concept study which demonstrates...